{"nctId":"NCT01046110","briefTitle":"Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin","startDateStruct":{"date":"2010-01"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":458,"armGroups":[{"label":"IDeg OD","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec"]},{"label":"DPP-IV inhibitor","type":"EXPERIMENTAL","interventionNames":["Drug: sitagliptin"]}],"interventions":[{"name":"insulin degludec","otherNames":[]},{"name":"sitagliptin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes (diagnosed clinically) for at least 6 months\n* Ongoing treatment with 1 or 2 of the following OADs (metformin, insulin secretagogue (sulphonylurea or glinides) or pioglitazone) in any combination with unchanged dosing for at least 3 months prior to Visit 1 with the minimum doses stated: -Metformin: alone or in combination (including fixed combination)1500 mg or maximum tolerated dose (at least 1000 mg daily) -Insulin secretagogue (sulfonylurea or glinide): minimum half of the maximal daily dose according to local labelling -Pioglitazone: minimum half of the maximal daily dose according to local labelling or maximum tolerated dose\n* Body Mass Index (BMI) below or equal to 40.0 kg/m\\^2\n* HbA1c 7.5-11.0 % (both inclusive) by central laboratory analysis\n\nExclusion Criteria:\n\n* Use within the last 3 months prior to Visit 1 of: exenatide, liraglutide, rosiglitazone or acarbose\n* Cardiovascular disease, within the last 6 months prior to Visit 1, defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty\n* Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)\n* Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the Investigator or hospitalisation for diabetic ketoacidosis during the previous 6 months\n* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate\n* Cancer and medical history hereof (except basal cell skin cancer or squamous cell skin cancer)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Glycosylated Haemoglobin (HbA1c)","description":"Change from baseline in HbA1c after 26 weeks of treatment","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.56","spread":"1.09"},{"groupId":"OG001","value":"-1.22","spread":"1.16"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG)","description":"Change from baseline in FPG after 26 weeks of treatment","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.22","spread":"3.17"},{"groupId":"OG001","value":"-1.39","spread":"3.11"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":226},"commonTop":["Headache","Diarrhoea","Nasopharyngitis","Nausea"]}}}